Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22258410 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TDO2MEN1KDM4ESMN1; SMN2 | |
| SCHEMBL1956794 | 0.81 | CYP2A6 (0.52) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL19054762 | 0.80 | CYP2A6 (0.56) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL15783990 | 0.80 | CYP2A6 (0.56) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| Ammonia Solution, Strong SCHEMBL16035727 | 0.78 | CYP2A6 (0.54) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL2221297 | 0.78 | MAPT (0.43) | CYP2A6CYP3A4ALDH1A1CYP1A2MEN1 | |
| SCHEMBL28146113 | 0.78 | TDO2 (0.45) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL29450604 | 0.76 | ALDH1A1 (0.58) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL221510 | 0.76 | ALDH1A1 (0.58) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 | |
| SCHEMBL2219704 | 0.75 | CYP2A6 (0.47) | CYP2A6CYP3A4ALDH1A1CYP1A2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011019651-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CYP2A6 2099/4885CYP3A4 959/4885ALDH1A1 1414/4885 |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | CYP2A6 311/4885CYP3A4 27/4885ALDH1A1 123/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CYP2A6 2099/4885CYP3A4 959/4885ALDH1A1 1414/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CYP2A6 2099/4885CYP3A4 959/4885ALDH1A1 1414/4885 |
| US-20110034497-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CYP2A6 2287/4885CYP3A4 1250/4885ALDH1A1 1282/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CYP2A6 2099/4885CYP3A4 959/4885ALDH1A1 1414/4885 |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | CYP2A6 2541/4885CYP3A4 1447/4885ALDH1A1 1938/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CYP2A6 761/4885CYP3A4 1322/4885ALDH1A1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.